Oruka Therapeutics stock surges as ORKA-001 psoriasis trial success puts $1.1bn biotech strategy to the test
Read More Technology News Can Albion and Tecnotree turn TELUS Corporation’s backend upgrade into a scalable VAS growth engine? Can Albion and Tecnotree help TELUS scale VAS into a growth engine? Discover what this telecom upgrade means for strategy, revenue, and competition. bySoujanya RaviApril 28, 2026